Notice Regarding Change in Management Structure

We hereby announce that our company will change its management structure effective April 1, 2026, as follows.

1. Change in Management Structure Our company will change its management structure on April 1, 2026, for the purpose of clearly separating the roles of supervision and execution and further strengthening corporate governance. Through this change, we aim to enhance the supervisory function of the Board of Directors by inviting outside directors who possess high-level expertise in management analysis and governance, and who are well-versed in the domestic and international pharmaceutical and healthcare industries. At the same time, we will introduce an executive officer system and delegate the authority of the President and Executive Officer to the respective unit heads of the business and corporate divisions, thereby realizing faster decision-making and clearer roles and responsibilities.

2. Board of Directors Structure (Effective April 1, 2026) Name / Title Keiko Oishi / Representative Director Shunji Katayama / Director Kazutaka Echigo / Director Eriko Kawai / Outside Director Christopher Alberney / Outside Director Stephen Engen / Outside Director Wataru Mochizuki / Auditor

3. Executive Officer Structure (Effective April 1, 2026) [Table content truncated in original source]